LCN2 of cerebrospinal fluid: A potential biomarker for diagnosis and disease progression in Alzheimer's disease
Authors:
- Qing-Ning ZhangQZQing-Ning Zhang
- Lan-Ke YuLYLan-Ke Yu
- Xin-Yuan ZhangXZXin-Yuan Zhang
- You WuYWYou Wu
- Heng ZhangHZHeng Zhang
- Jia-Lin WuJWJia-Lin Wu
- Zhao-Hui YaoZYZhao-Hui Yao
- For The Alzheimer'S Disease Neuroimaging InitiativeFIFor The Alzheimer'S Disease Neuroimaging Initiative
- 27 June 2025
- journal article
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 106 (4) , 1573-1581
Abstract
Background: Alzheimer's disease (AD) is a neurodegenerative disorder with complex pathological features and pathogenesis, involving aspects such as amyloid-β (Aβ) deposition and neuroinflammation. AD lacks the specific biomarkers for diagnosis, which restricts diagnosis. Recent studies have indicated that Lipocalin-2 (LCN2) plays a direct or indirect role in the occurrence and development of AD. However, whether LCN2 can serve as a biomarker for AD diagnosis remains unclear. Objective: This study aims to investigate the role of LCN2 in AD and its potential as a biomarker for diagnosis from a clinical perspective. Methods: We analyze the participant demographic information, LCN2 and Aβ 42 levels in cerebrospinal fluid (CSF), and cortex thickness from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database with Welch ANOVA, Linear regression models and other statistical methods. Results: LCN2 levels in the CSF of AD patients were significantly higher than those in individuals with mild cognitive impairment and no cognitive impairment. The LCN2 levels were closely associated with cognitive decline and pathological features of AD, including Aβ deposition, and reduced cortical thickness, but no tau protein phosphorylation. Age was an important confounding factor affecting the relationship between LCN2 and Aβ 42 , while gender, years of education, and APOE carrier status did not have a significant impact. Furthermore, LCN2 was linked to the upregulation of inflammatory markers, indicating its potential involvement in the neuroinflammatory processes of AD. Conclusions: LCN2 is not only a potential biomarker for the early diagnosis of AD but may also play a significant role in the neurodegenerative processes associated with the disease.Keywords
Funding Information
- National Natural Science Foundation of China (82271214)
This publication has 53 references indexed in Scilit:
- Maternal phthalates exposure promotes neural stem cell differentiation into phagocytic astrocytes and synapse engulfment via IRE1α/XBP1s pathwayCell Reports, 2025
- Amyloid β oligomer promotes microglial galectin-3 and astrocytic lipocalin-2 levels in the hippocampus of mice fed a high-fat dietBiochemical and Biophysical Research Communications, 2023
- Kdm6a deficiency in microglia/macrophages epigenetically silences Lcn2 expression and reduces photoreceptor dysfunction in diabetic retinopathyMetabolism, 2022
- Lipocalin-2: Structure, function, distribution and role in metabolic disordersBiomedicine & Pharmacotherapy, 2021
- Astrocyte‐derived lipocalin‐2 mediates hippocampal damage and cognitive deficits in experimental models of vascular dementiaGlia, 2017
- Roles of NGAL and MMP-9 in the tumor microenvironment and sensitivity to targeted therapyBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2016
- Differential Roles of M1 and M2 Microglia in Neurodegenerative DiseasesMolecular Neurobiology, 2015
- FreeSurferNeuroImage, 2012
- Siderocalin (Lcn 2) Also Binds Carboxymycobactins, Potentially Defending against Mycobacterial Infections through Iron SequestrationStructure, 2005
- Lipocalins: unity in diversityBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 2000